← board
RNAZ
TransCode Therapeuticsdistress 7/10 · high distress / dilution risk$7.97-5%today-48% from 52w high
Oncology 1
Lead: colorectal cancer · est. market ~$12B (approx, global)
Revenue
pre-revenue
Liquidity
$13M
Runway
0.6 yrs
Shares 1y
+14%
Price & events
-14.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-5.1%
1D
-3.6%
1W
+64.2%
1M
-8.1%
3M
-19.3%
6M
-29.3%
1Y
-97.2%
2Y
-100.0%
5Y
-100.0%
All
Overview
- Market Cap
- $7.57M
- Volume
- 2.42K
- 52 Week Range
- $4.55 – $15.23
- Total Shares
- 950.30K
- Float Shares
- 865.76K
- Short %
- 5.56%
- % Held by Insiders
- 8.90%
- % Held by Institutions
- 7.63%
- RVOL
- 0.10x
- Beta
- 1.24
Pipeline stages · 1 programs
TTX-MC138
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-09-30 | Phase 1/2 | TTX-MC138 | Advanced Solid Tumor | 16 | active not recruiting |
Catalyst news & presentations · 5
- first half of 2026trial initiationsecondaryPhase 2TTX-MC138 · Phase 2a dose-expansion trial of TTX-MC138 in ctDNA-positive colorectal cancer patientsSEC 8-K
- 2026-03-02partnershipgenetically-engineered adenoviruses · Exclusive licensing agreement with Unleash Immuno Oncolytics for pre-clinical cancer programSEC 8-K
- February 5, 2026regulatory submissionFiled (NDA/BLA)TTX-MC138 · Submitted IND amendment for Phase 2a trial in MRD setting.SEC 8-K
- 2025-12-11partnershipTTX-MC138 · Collaboration with Quantum Leap to evaluate TTX-MC138 in PRE-I-SPY platformSEC 8-K
- October 17-21, 2025conferencedata presentationsecondaryPhase 1TTX-MC138 · Presentation of Phase 1a preliminary data at ESMO Congress.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-04-16HC Wainwright & Co.Buy
- 2025-03-13HC Wainwright & Co.Buy
- 2025-02-07HC Wainwright & Co.Buy
- 2025-02-06HC Wainwright & Co.Buy
- 2024-12-18HC Wainwright & Co.Buy
- 2024-11-15HC Wainwright & Co.Buy
Competitors — colorectal cancer
- ABBVAbbVie Inc.$451.1B · D2
- NVSEFNOVARTIS AG$292.0B · D3
- RVMDRevolution Medicines, Inc.$40.3B · D1
- BNTXBioNTech SE$23.1B · D1
- SMMTSummit Therapeutics Inc.$11.6B · D3
- IDYAIDEAYA Biosciences, Inc.$3.0B · D3
- VSTMVerastem, Inc.$515M · D5
- CRDFCardiff Oncology, Inc.$59M · D3
- CNTXContext Therapeutics Inc.$57M · D2
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-21TransCode Therapeutics, Inc. (RNAZ) 8-K: Key Nasdaq Approvals and Stockholder Vote Results July 2026 - Minichart
- 2026-07-20TransCode Therapeutics Shareholders Approve Key Capital Measures - TipRanks
- 2026-07-20TransCode Therapeutics (RNAZ) AGM 2026 Summary - Quartr
- 2026-07-18Form 13D/A TransCode Therapeutics For: 17 July By Investing.com - Investing.com Nigeria
- 2026-07-17TransCode Therapeutics Updates Preferred Stock Ownership Limits - TipRanks
- 2026-07-17TransCode Therapeutics (RNAZ) investor to convert preferred stock toward 9.99% stake - Stock Titan
- 2026-07-15Transcode Therapeutics Inc (NASDAQ: RNAZ) Share Price, RNAZ Stock News, RNAZ Share Price & Updates - Kalkine
- 2026-07-14Understanding Momentum Shifts in (RNAZ) - Stock Traders Daily
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.